Loading
Lenalidomide alone delayed progression to active myeloma in people with intermediate- or high-risk smouldering disease, but side effects led many to stop, and it did not improve survival.
Phase 2/3 trial randomising 182 patients with intermediate- or high-risk smouldering myeloma to lenalidomide 25 mg or observation.
Three-year progression-free survival was 91 percent with lenalidomide against 66 percent with observation (hazard ratio 0.28), with the largest benefit in high-risk patients; about half of treated patients discontinued for toxicity.
Lenalidomide showed that intervening before symptoms can delay end-organ damage, supporting later trials such as AQUILA, but tolerability limits its use as a single agent.
Shares Smouldering multiple myeloma, Lenalidomide.
Shares Lenalidomide, Journal of Clinical Oncology.
Shares Smouldering multiple myeloma, Lenalidomide.
Shares Lenalidomide, Journal of Clinical Oncology.
Shares Smouldering multiple myeloma, Lenalidomide.
Shares Lenalidomide, Journal of Clinical Oncology.